Uniseed has a commitment, through pre-seed and seed stage venture capital investment, to successfully commercialise the outcomes of Australian research and ingenuity from the University of Queensland, the University of Melbourne and the University of New South Wales.

It represents an important step in forging a link between academia and business that focuses on the commercialisation of innovative ideas and inventions for global consumption.

Uniseed has strong capabilities to package research outcomes from the academic research environment.

Uniseed began as a $20 million fund, founded by the Universities of Queensland and Melbourne. Since then, through investment commitment from Westscheme, Western Australia's largest non-government superannuation fund, the University of New South Wales and further investment from the founding Universities, the fund has grown to over $60 million.


 
::


::



::


::



::



::


::



::



::


::


::


::


::

::


::


::

::

QRx Pharma Releases Additional Phase 3 Data for Q8003IR 'Dual Opioid' Pain Therapy

QRx Pharma Releases Successful Phase 3 Study Results for 'Dual Opioid' Pain Therapy

Fultec: Top Four Modem Manufacturers adopt Fultec TBUs

BT Imaging raises A$3 million Series A Funding


Uniseed CEO, Peter Devine's interview with PharmaTelevision


Hatchtech headlice treatment moves to Phase II after US FDA approval

Hatchtech Appoints Stewart Washer as new Chairman

Uniseed Investee Companies Raise Over $20m in Follow-on Funding


QRx Enrolls First Patients in Phase III Clinical Trial Program for its 'Dual Opioid' Pain Therapy


Universities catch the goose but fail to gather the golden eggs

Uniseed investee Colocare Holdings to merge with Continence Control Systems

Uniseed investee Adipogen to merge with Autogen to form Verva Pharmaceutial

Cryptopharma raises $0.8m to progress cystic fibrosis drug

New Investment Manager joins Uniseed

QRxPharma trials recipe for pain relief

Chairman recognised on the Queen's birthday honours list

QRxPharma completes $50m IPO

Hatchtech head lice lotion passes Phase I trial

Polyvacc heralds vaccine technology breakthrough

Uniseed article in The Australian

Uniseed appoints new CEO

::
::
:: $1.67 million grant to develop pain drug 
:: Investment to commercialise hydrogen technology
:: Investors back anti-fogging technology
 
 
© 2007 Uniseed Pty Ltd